Neoadjuvant Chemotherapy With Selpercatinib for Locally Advanced RET Fusion-Positive Papillary Thyroid Carcinoma: A Case Report

局部晚期RET融合阳性乳头状甲状腺癌新辅助化疗联合塞帕替尼:病例报告

阅读:3

Abstract

A 65-year-old male presented to our hospital with a complaint of a left cervical mass. The left supraclavicular lymph node was enlarged, measuring 77 mm, and biopsy results confirmed metastasis of papillary thyroid carcinoma (PTC). The left supraclavicular lymph node extended to the upper mediastinum and invaded the internal jugular and subclavian veins, with suspicion of common carotid and subclavian artery invasion. Surgical resection was deemed infeasible. The Oncomine Dx Target Test system, a gene panel test using a next-generation sequencer, of the metastatic lymph node was positive for RET fusion (CCDC6-RET), and selpercatinib treatment was initiated. After 4 months, the tumor reduced in size, and surgery was performed. The postoperative course was uneventful, with ongoing follow-up. This case is a successful case of neoadjuvant chemotherapy for RET fusion-positive PTC with local regional progression.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。